Lightnews — Scholar-powered news

Vun-Sin Lim, PhD @vslim.bsky.social · 2d

Getting ready for #IASLC Asia Conference on Lung Cancer this week!

Want to know more about #JTO #JTOCRR publications or Reviewer Workshop? Happy to connect in person.

#ACLC25 @iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social #PeerReview #ScholarlyPublication

1 2

Vun-Sin Lim, PhD @vslim.bsky.social · 20d

#WCLC25 It takes a village!

Thanks to all our dedicated editors, reviewers, our publisher and my editorial office teams! Thanks for the support from our authors and @iaslc.bsky.social!

@jtoonline.bsky.social @elsevierhms.bsky.social #JTO #JTOCRR

1 1

Vun-Sin Lim, PhD @vslim.bsky.social · 20d

#WCLC25 Meet the Editors - Engaging Q&A session between meeting attendees and Editors-in-Chief, Dr Alex Adjei #JTO and Dr Emily Stone #JTOCRR.

@iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social #scholarlypublishing

1

Reposted by Vun-Sin Lim, PhD

D. Ross Camidge @drcamidge.bsky.social · 22d

kdvr.com/news/health/...

kdvr.com

2 2

Vun-Sin Lim, PhD @vslim.bsky.social · 29d

1

Vun-Sin Lim, PhD @vslim.bsky.social · 29d

#JTO & #JTOCRR Editorial Reception

This annual get-together at #WCLC25 lets editors, top reviewers, the editorial office teams and publisher reconnect in person in a meaningful way in the middle of a very busy conference.

@iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social

1 1

Vun-Sin Lim, PhD @vslim.bsky.social · 29d

@iaslc.bsky.social @jtoonline.bsky.social #WCLC25 #peerreview

1

Vun-Sin Lim, PhD @vslim.bsky.social · 29d

#WCLC25 Reviewer Workshop - Here are the next generation of reviewers!

It’s heartwarming to know many attendees came here just for this workshop. A few dedicated participants attended online despite unforeseen circumstances. I’m grateful for all of you, faculty and participants.
@iaslc.bsky.social

1 2

Vun-Sin Lim, PhD @vslim.bsky.social · Sep 9

#WCLC25 Happening now: IASLC Reviewer Workshop. Alex Adjei - “Top 10 of the do’s and dont’s as a reviewer”

@iaslc.bsky.social @jtoonline.bsky.social #JTO #JTOCFR #peerreview

Vun-Sin Lim, PhD @vslim.bsky.social · Sep 6

#WCLC25 Our #JTO editors got many talents!

@drtomjohn.bsky.social @drsanjaypopat.bsky.social @jtoonline.bsky.social @iaslc.bsky.social

Prof Tom John @drtomjohn.bsky.social · Sep 6

Looking forward to playing with @drsanjaypopat.bsky.social - a lot of fun rehearsing covers and @mayhemtomi tracks. Check us out tonight @iaslc.bsky.social #wclc2025

1

Reposted by Vun-Sin Lim, PhD

Prof Tom John @drtomjohn.bsky.social · Sep 6

Looking forward to playing with @drsanjaypopat.bsky.social - a lot of fun rehearsing covers and @mayhemtomi tracks. Check us out tonight @iaslc.bsky.social #wclc2025

1 3 8

Vun-Sin Lim, PhD @vslim.bsky.social · Sep 6

#WCLC25 WS04: Joint IASLC-CSCO-CAALC session happening now in Room 06.

Case presentations and discussions with the panelists with global perspectives.

@iaslc.bsky.social

Vun-Sin Lim, PhD @vslim.bsky.social · Sep 5

Read the special article at #JTO: jto.org/article/S155...

"Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction"

@jtoonline.bsky.social

Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction

Copy number alterations of chromosome 9p, or parts thereof, impair immune response and confer immune-checkpoint therapy (ICT) resistance by direct elimination of immune-regulatory genes on this arm, n...

jto.org

Vun-Sin Lim, PhD @vslim.bsky.social · Sep 5

🆕Special article by Lippman and colleagues in #JTO

📰Press release by UCSD: today.ucsd.edu/story/cancer...

@ucsdcancer.bsky.social @iaslc.bsky.social @sciencedirect.bsky.social @elsevierhms.bsky.social @jtoonline.bsky.social #LCSM

Cancer Breakthrough Sparks New Vaccine

Researchers at UC San Diego and their collaborators have helped answer one of the most difficult questions in oncology: why do some tumors not respond to immunotherapy?

today.ucsd.edu

1

Reposted by Vun-Sin Lim, PhD

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · Jul 1

Early weight gain as a risk factor for increased maximum weight gain among NSCLC patients on lorlatinib & other ALK tyrosine kinase inhibitors - JTO Clinical and Research Reports.

#LCSM #LungCancer
www.jtocrr.org/article/S266...

2 4

Vun-Sin Lim, PhD @vslim.bsky.social · Jun 27

✍️June #JTO Editor’s pick 3 of 4: Deuterated Osimertinib

🆓 access: www.jto.org/article/S155...

📎 Also see Deuterated Lorlatinib: www.jto.org/article/S155...
📎 Accompanying editorial: www.jto.org/article/S155...

@jtoonline.bsky.social @iaslc.bsky.social @elsevierhms.bsky.social #LCSM

IASLC @iaslc.bsky.social · Jun 27

Han et al. evaluated 105 patients with advanced EGFR-mutated NSCLC while treating them with TY-9591, a deuterated osimertinib derivative, in this dose-escalation and dose-expansion study. They found that TY-9591 reported favorable safety and substantial efficacy.

Check it out: bit.ly/4dUc2p9

Vun-Sin Lim, PhD @vslim.bsky.social · Jun 9

🆕 #JTO Review Article from the #IASLC Basic and Translational Science Committee
🆓 access to full texts 🔗 jto.org/article/S155...

@jtoonline.bsky.social @iaslc.bsky.social @elsevierhms.bsky.social #lungcancer

Vun-Sin Lim, PhD @vslim.bsky.social · May 14

🆕 #JTO Review Article from IASLC Advanced Radiation Technology subcommittee

🔗 www.jto.org/article/S155...

#OpenAccess @iaslc.bsky.social @jtoonline.bsky.social @elsevierconnect.bsky.social

The OncoAlert Network 🚨 @oncoalert.bsky.social · May 14

Emerging Role of Targeted Therapies Combined with Radiotherapy in Inoperable Stage I-III, Non-Small Cell Lung Cancer (NSCLC)
www.jto.org/article/S155...

The review also examines the incidence of actionable mutations, toxicity considerations, sequencing strategies, and ongoing trials

Reposted by Vun-Sin Lim, PhD

Dr. Herbert Loong @herbloongmd.bsky.social · May 7

Come join us in #hongkong 🇭🇰 🍜🥟🥡 for the #inaugural @myesmo.bsky.social #ESMOTATAsia25 on July 18-20, 2025! We have assembled a #stellar group of #international #faculties and #experts in #drugdevelopment to help move the field forward. Register today!

2 4

Vun-Sin Lim, PhD @vslim.bsky.social · Apr 19

🗳️ Vote for him to make a difference in the lung cancer sphere!

🔗 www.iaslc.org/2025-preside...

@jtoonline.bsky.social #JTO

2025 President-Elect Candidates | IASLC

The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies.

www.iaslc.org

Vun-Sin Lim, PhD @vslim.bsky.social · Apr 19

Full support to Alex Adjei for President-Elect in 2025 #IASLC Board of Directors Election!

I have worked with him for 10+ years, inspired by his strong leadership, vision, advocacy, and dedication to patient care, research and publication, and mentoring the next generations.
@iaslc.bsky.social

1 1

Vun-Sin Lim, PhD @vslim.bsky.social · Mar 28

@jtoonline.bsky.social @iaslc.bsky.social #JTO #sclc

The OncoAlert Network 🚨 @oncoalert.bsky.social · Mar 11

Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer #SCLC : the phase I/II LUPER study

www.jto.org/article/S155...

The combination demonstrated promising efficacy and a manageable safety profile, particularly for platinum-sensitive patients, warranting further investigation.

1 2

Reposted by Vun-Sin Lim, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · Mar 11

Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer #SCLC : the phase I/II LUPER study

www.jto.org/article/S155...

The combination demonstrated promising efficacy and a manageable safety profile, particularly for platinum-sensitive patients, warranting further investigation.

1 2

Reposted by Vun-Sin Lim, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · Mar 18

Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON)

www.jto.org/article/S155...

These findings suggest that gut microbiota profiling could help optimize treatment strategies for NSCLC.

3 7